Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV
Status:
RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn whether it is possible to use intramuscular (IM) ketamine in combination with psychotherapy to treat moderate-to-severe methamphetamine use disorder (MeUD) in publicly insured patients with or at-risk for HIV disease. The main questions it aims to answer are:
* Do publicly insured patients find ketamine-assisted psychotherapy feasible and acceptable as a potential treatment for MeUD?
* Is IM ketamine safe and tolerable among patients with MeUD?
Participants will:
* Receive 3 monitored doses of IM ketamine
* Have 3 preparation and 4 integration psychotherapy visits
* Report their daily amounts of methamphetamine used prior to, during, and up to 3 months following the intervention
Phase:
PHASE2
Details
Lead Sponsor:
Nicky Mehtani, MD, MPH
Collaborators:
California HIV/AIDS Research Program National Center for Advancing Translational Sciences (NCATS) San Francisco Department of Public Health